Europe's drug market is outpacing enforcement
Europe’s drug market is morphing faster than authorities can track it — and the human cost is rising. That’s the central warning from the European Union Agency for Drugs (EUDA), the EU’s specialized body for monitoring drug trends across the bloc, in its annual report published Tuesday, June 9. The report draws on data collected through 2025 from all 27 EU member states plus Norway and Turkey, and paints a picture of a market that is fragmenting, diversifying and growing harder to intercept, in every sense of the word.
At a Glance
At least 7,600 overdose deaths were recorded across 29 countries in 2024, with opioids — often combined with other substances — remaining the leading cause of drug-related fatalities.
EUDA now monitors approximately 1,050 substances, after 50 new psychoactive substances were detected for the first time in Europe in 2025 alone — roughly one new substance per week.
Cocaine seizures fell in volume (330 metric tons intercepted in 2024, down from 419 in 2023) but rose in frequency (97,000 interceptions versus 95,000), suggesting traffickers have shifted to smaller, more fragmented shipments to evade detection.
This image is used for illustrative purposes only.
Synthetic opioids: a near-zero margin between use and death
The term novel psychoactive substances — NPS in shorthand — covers a stark reality: molecules engineered to mimic the effects of known illegal drugs, typically synthesized faster than surveillance systems can identify them. In 2025, seven new synthetic opioids were flagged through the EU’s Early Warning System (EWS), a real-time monitoring network established in 1997. Among them: nitazenes and benzimidazole opioids, two substance families whose potency can exceed that of fentanyl — the opioid at the center of the overdose crisis that has ravaged communities across the United States.
Lorraine Nolan, executive director of EUDA, put the danger in clinical terms: a single gram of some of these compounds is sufficient to produce several thousand lethal doses. The margin between a recreational dose and a fatal one is, in practice, nearly nonexistent. What compounds the risk is ignorance — users often don’t know what they’re consuming, as these substances are frequently mixed into other drugs without disclosure.
The pace itself is alarming. Seven new entries in the opioid category in 2025 alone suggests that surveillance capacity may be struggling to keep pace with the innovation coming out of clandestine laboratories.
Cannabis: an “established” market growing more potent
Cannabis remains Europe’s most widely used illegal drug, with 24.9 million adults reporting use in the past year. What the EUDA report flags is a qualitative shift in supply. Products from partially legalized markets — notably Canada and several U.S. states — are entering European markets in growing volumes. At the same time, THC concentrations (THC being the psychoactive compound in cannabis) are climbing in certain products. According to Nolan, some cannabis resin now tests at up to 33% THC. Scientific literature has documented a link between prolonged use of high-potency cannabis and psychotic episodes, though the causal relationship depends on individual vulnerability and patterns of use.
Two additional trends concern EUDA: the adulteration of cannabis products with potent synthetic cannabinoids — compounds whose effects can be unpredictable and severe — and the sale of these blends in the form of vapes and edibles. These consumption formats, perceived as lower-risk by inexperienced users, may be drawing in younger or first-time consumers who are less equipped to gauge dosing or recognize adverse reactions.
Cocaine fragments; ketamine takes hold
The drop in cocaine seizure volumes — 330 metric tons intercepted in 2024, down from 419 the year before — might look like a win for law enforcement. EUDA urges caution. The number of individual seizures actually rose over the same period, from 95,000 to 97,000. This divergence between total volume and interception frequency points to a tactical adaptation by trafficking networks: smaller loads, more dispersed, harder to flag at checkpoints. That reads less like a weakened trade than like one that has internalized enforcement patterns into its operating model.
Cocaine also continues to drive treatment demand: it contributes to a growing share of addiction treatment admissions across Europe. Roughly 4.3 million Europeans between the ages of 15 and 64 reported using it in the past year.
The report also flags ketamine — a legitimate clinical anesthetic — as an emerging concern. Its recreational use remains “relatively low” overall, but EUDA notes it is spreading in nightlife settings popular with younger adults. The agency considers it a signal worth tracking before it escalates.
Analysis — when markets move faster than policy
The EUDA report describes a landscape that national public health systems are struggling to keep up with. Three structural dynamics stand out.
The first is the speed of chemical innovation. Clandestine laboratories — often located outside EU territory — produce new molecules at a pace that routinely outstrips classification and scheduling procedures. The result is a temporary legal window that is commercially exploited before national or EU legislators have time to respond.
They are not yet illegal at the moment they become dangerous.
The second is the fragmentation of distribution networks. Smaller shipments, secondary ports, high-speed maritime transfers, drones, semi-submersibles, sophisticated concealment techniques — these are not signs of a weakened trade. They are signs of a trade that has adapted. European customs authorities are facing an adversary that updates its methods in real time, eroding the effectiveness of fixed enforcement infrastructure.
The third is the normalization of consumption formats. Vapes loaded with synthetic cannabinoids or high-concentration edibles bear no resemblance to the products that decades of prevention campaigns were designed around. They circulate among user populations that may not associate these formats with risk. That invisibility could be the most consequential vector of harm over the medium term.
EUDA’s recommendations — invest in prevention, treatment and social reintegration; maintain a public-health-centered approach — are sound. But they require coordination across 27 national health systems with vastly different capacities, political cultures and fiscal headroom.
The Bottom Line
This report lands at a moment when several EU member states are actively debating cannabis regulation, and when the EU itself is searching for coherent internal security frameworks amid jealously guarded national competences. The question the EUDA data really poses isn’t “how much drugs are circulating in Europe?” — it’s whether 27 governments are prepared to treat this as a shared European problem, or as 27 separate national ones. The answer to that question will determine whether the next annual report records progress — or further evidence of how quickly illicit markets adapt.
Sources: Euronews · RFI · AFP